Event | Change in prescription | Respondent (N, %)* |
---|---|---|
Any | None | 0 (0%) |
< 2ULN ALT/AST | Reduce dose | 36 (24%) |
< 2ULN ALT/AST | Suspend drug | 9 (6%) |
2–3 ULN ALT/AST | Reduce dose | 29 (19%) |
2–3 ULN ALT/AST | Suspend drug | 16 (11%) |
> 3 ULN ALT/AST | Reduce dose | 6 (4%) |
> 3 ULN ALT/AST | Suspend drug | 12 (8%) |
Multiple rising ALT/AST with most recent < 2 ULN ALT/AST | Reduce or suspend drug | 19 (13%) |
Multiple rising ALT/AST with most recent 2–3 ULN ALT/AST | Reduce or suspend drug | 12 (8%) |
Multiple rising ALT/AST with most recent > 3 ULN ALT/AST | Reduce or suspend drug | 7 (5%) |
Other | Individual | 4 (3%) |